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Abstract
Translational Research (TR) provides a set of tools and communication context for scientists and
clinicians to optimize the drug discovery and development process. In the proceedings of a
Princeton conference on this timely topic, the strengths and needs of this developing field were
debated. Outcomes and key points from these discussions are summarized in this article which
covers the topics of defining what we mean by translational research (both theoretically and in
operational terms), ways in which to engender the TR mindset and embed it in organizations such
as the pharmaceutical industry in order to optimize the impact of available technologies (including
imaging methods), the scientific basis and under-pinnings of TR including genomics knowledge,
information sharing, as well as examples of application to drug discovery and development.
Importantly, it should be noted that collaborations and communications between the stakeholders
in this field, namely academia, industry and regulatory authorities, must be strengthened in order
for the promise of TR to be delivered as better therapies to patients.
Introduction
There are many challenges facing pharmaceutical compa-
nies in the post-genome era not least of which is declining
productivity and innovation. Not surprisingly, there is
agreement between Industry, Academia and Regulatory
communities that the drug discovery and development
process needs to change in order to meet the future needs
of patients with effective and desirable drugs. A key part of
the strategic solution is to leverage the application of TR
principles and practices, which if implemented will go a
long way towards addressing the challenge posed by
FDA's Critical Path Initiative [1] (for more detail on this
initiative see section on "Optimizing the Impact of TR"
and http://www.fda.gov/oc/initiatives/criticalpath/white
paper.pdf). Successful drug development requires satisfy-
ing a matrix of domains from relevance to the disease and
the drug-ability of the target through feasibility and con-
venience of drug delivery, demonstration of favorable
benefit-risk profile in order to achieve to a drug label that
reflects physician and patient acceptance. Herein lies a key
role for TR in helping to navigate this journey.
In order to promote discussion on this topic, the Interna-
tional Quality and Productivity Center (IQPC) organized
a  Translational Research Conference (20–22 September
2004 Princeton, NJ) that hosted a small group of clinical
and basic science researchers and individuals from the
pharmaceutical industry. Among the topics discussed
were how to define "Translational Research", how to
expedite the transfer of pre-clinical findings to influence
development plans, how to select biomarkers to ensure
support for decisions, how new strategies can be effec-
Published: 20 December 2004
Journal of Translational Medicine 2004, 2:44 doi:10.1186/1479-5876-2-44
Received: 09 December 2004
Accepted: 20 December 2004
This article is available from: http://www.translational-medicine.com/content/2/1/44
© 2004 Hörig and Pullman; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Translational Medicine 2004, 2:44 http://www.translational-medicine.com/content/2/1/44
Page 2 of 8
(page number not for citation purposes)
tively translated to practical tactics, and what team players
and collaborations are necessary to conduct successful TR.
Success factors identified include: Identification and vali-
dation of novel drug targets, development of robust and
validated assays to screen drug leads for safety and poten-
tial efficacy in humans, and the identification of suitable
patients for expedited but informative trials.
Defining Translational Research
While the goal of TR is to implement in vivo measure-
ments and leverage preclinical models that more accu-
rately predict drug effects in humans, TR itself can be
defined in many ways. At its core however, is the thesis
that information gathered in animal studies can be trans-
lated into clinical relevance and vice versa, thus providing
a conceptual basis for developing better drugs. It could in
fact be argued that the designation of a special term or def-
inition for TR might be unnecessary or even misleading.
Historically the term was assigned to create awareness and
advocacy for the general public, clinicians and scientific
communities, and especially for the government and
other private sponsors [2] in this evolving discipline.
Nonetheless, the basis for TR lies in sound scientific and
clinical research principles.
Whatever the precise definition TR, it should serve as a
forum to find a "common language" for clinicians and sci-
entist in navigating the complexities of basic scientific
approaches, data analysis and information processing. It
clearly implies the need for an intensive training for scien-
tists and clinicians in multiple disciplines to acquire
expertise and experience to conduct TR. For the purposes
of this symposium, the scope of translational research was
defined as the application of scientific tools and methods
to drug discovery and development. This can be achieved
by integrating information concerning a) exposure (phar-
macokinetics), b) biological activity (pharmacodynamics
including safety profiles) delineating differences between
species and leading to the validation of target and mecha-
nism biomarkers, and c) outcomes leading to an under-
standing of efficacy and safety between species and
ultimately to the qualification or linkage of biomarkers to
clinical outcome (for a fuller discussion on Biomarkers
and Surrogate Endpoints see definitions in [3]). Thus TR
can be used to mitigate risk and enhance drug develop-
ment opportunities.
Therefore, in taking a pragmatic or operational rather than
a definitional approach, a key to a successful translation
of non-human research to human clinical trials lies in the
choice of biomarkers. While biological pathways tend to
be homologous across species and more so than pharma-
cokinetic parameters such as absorption and clearance,
animal models themselves have a poor record of predict-
ing human disease outcome. Nonetheless, biomarkers are
the key for prediction of biological activity if not drug effi-
cacy in humans. At least three types of biomarkers can be
identified: (1) target biomarkers measuring the interac-
tions between a drug and its target; (2) mechanism
biomarkers measuring their downstream biological effects
and (3) outcome biomarkers that reflect efficacy and
safety. A second dimension can also be ascribed to
biomarkers to help drug developers assign risk assessment
to such approaches. This sub-classification links desired
utility to points on a risk continuum; e.g. low, medium
and high, in which 'low' describes a biomarker applied
solely to animal models for example for selecting com-
pounds for progression into humans, whereas 'medium'
is association with utility for some aspects of early clinical
profiling of efficacy and safety including across species
correlation, and 'high' is associated with reproducibility
and qualification as an outcome or even regulatory tool in
humans.
Additionally, TR itself undergoes an evolution from path-
finding (hypothesis generating) to discovery research, to
development, and finally to application. Each of these
operational phases is amenable to being evaluated or sup-
ported by biomarkers, either for the definition of objec-
tives, proof of principle or in assessing risk and feasibility.
Consequently the right choice of biomarkers can help
drive decision-making and lower the costs and cycle-time
for progression of a new drug from the bench into the
clinic. In summary, whatever the definition or classifica-
tion ultimately used, in practical terms translational tools
should be developed and applied on a "fit for purpose"
basis with prior assessment and agreement of attendant
risks.
Optimizing the Impact of Translational 
Research
Traditional Research and Development (R&D, also
referred to as Discovery and Development) paradigms
have accentuated the boundaries between the territories
of discovery and development worlds and have not been
conducive to bridging key transition points. This is unfor-
tunate since the development world tends to lag behind
advances made in discovery, a point recognized by FDA in
launching the Critical Path Initiative [1]. In brief, this ini-
tiative challenges Industry and others to develop and
implement better tools, such as biomarkers, trial mode-
ling and simulation and other solutions, in order to opti-
mize the development and regulatory stages of a product's
life.
While advances have been made on streamlining forward
progression of R&D through organizational linkages,
what has not happened to the same degree is a bi-direc-
tional flow of information, namely flow of information
from the clinic (e.g. clinical validation or lack thereof)Journal of Translational Medicine 2004, 2:44 http://www.translational-medicine.com/content/2/1/44
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back into the hands of the discovery scientist. The conse-
quence of this is that the biological models used to qualify
drug candidates may fail to be predictive of subsequent
drug responses in the clinical setting. Thus a practical out-
come of TR is to improve the overall probability for tech-
nical success (POS) in drug development.
Consequently the next paradigm for R&D optimization
depends not only on leveraging emerging technologies
such as pathway mapping and in silico modeling, but also
the need to empower key scientists and clinicians with the
task of enhancing the prediction and iteration learning
cycle. Since there are different organizational solutions for
embedding the TR mindset within an organization, a key
element is to provide TR expertise to drug development
teams. Furthermore, innovation and productivity values
are critically linked through information exchange. Rapid
iteration (e.g., learn-confirm cycles) and transfer of
knowledge gained from prototype development experi-
ence will enable more rapid compound redesign against
the highly desired target and be reflected as enhanced
innovation. On the productivity side, the tools outlined in
the Critical Path Initiative [1], once effectively imple-
mented, will lead to enhanced development productivity
but only if information exchange occurs efficiently across
different functions. Hence a backbone for TR is support by
user-friendly informatics systems.
The journey however starts at understanding the scientific
foundations of physiology and pathophysiology, thus
providing a rational linkage between the gene, its
expressed product, disease expression and ultimately out-
come. The discipline of biomarker identification and
development as mentioned previously encompasses these
principles and is a core tool in the TR scientist's armamen-
tarium.
Biomarkers (which are not necessarily Surrogate end-
points and few are in fact) are key tools for escorting the
drug candidate from the bench to the bedside and back.
That is they can be both animal "diagnostic" as well as
human "diagnostic" tools. A key implementation tool is
therefore to identify early on which biomarkers may be of
value and to study these in the relevant animal models,
that is, specifically include them in preclinical screening
paradigms, as well as identify their role (e.g., go / no go
decision factors) in the clinical development plan.
Biomarkers, which include imaging techniques as well as
protein and genetic markers, may fulfill several roles in
R&D from compound screening and selection through
dose justification, decision-making and risk mitigation,
however the key is to overtly link them to the discovery
and development plans with a priori agreed performance
characteristics, such that there is agreement on the utility
of the marker.
There are many good examples of the value or non-value
of preclinical models in predicting subsequent human
response and safety. The journey from preclinical experi-
ence to the clinic is a well-worn one (e.g., Xenograft test-
ing for oncology), albeit without the degree of overall
predictiveness we would desire. On the other hand there
is a marked paucity of examples in which clinical experi-
ence or observation was translated back into a legitimate
drug target and discovery effort (e.g. Viagra). Thus, a
major opportunity lies in both developing more sensitive
and specific animal models of disease (e.g. knock in/out)
as well as fully leveraging novel clinical observations. At
the same time it is the ultimate validation in the clinic that
counts, and rapid feedback of that information will allow
the conditional probabilities and learning cycle to be
enhanced. By enabling these principles through organiza-
tional and cultural change, the impact of TR will be deter-
mined by direct impact on high-quality mid-phase
transitions as well as reduced cycle-times and resource
burdens.
Basic science, genomics and Translational 
Research
The era of genome-scale biology has seen an increase in,
and production of, vast amounts of biological data
together with an extensive increase in biology-oriented
databases. To make the best use of biological databases
and the knowledge they contain, different kinds of infor-
mation from different sources must be integrated in ways
that make sense to biologists. A major component of the
integration effort is the development and use of annota-
tion standards such as ontologies. Ontologies offer a con-
ceptualization of domains of knowledge and facilitate
both communication between researchers and the use of
domain knowledge by computers for multiple purposes.
Therefore, the Gene Ontology (GO) project was founded
in 1998, in an attempt to provide consistent descriptors
for gene products, in different databases; and to standard-
ize classifications for sequences and sequence features.
Since then, the GO Consortium has grown to include
many databases, including several of the world's major
repositories for plant, animal and microbial genomes [4].
Despite vast differences in genome size among various
species, genes can be highly conserved at the level of pro-
tein sequence allowing searching for an unknown human
protein function in yeast. As new genome sequences are
being rapidly generated, and where comparative genome
analysis requires the integration of data from multiple
sources, it is especially relevant to provide rigorous ontol-
ogies that can be shared by the scientific community at
large.
In the past, biological processes and the underlying genes,
proteins, other molecules and environmental factors,
have been studied separately more than on an integratedJournal of Translational Medicine 2004, 2:44 http://www.translational-medicine.com/content/2/1/44
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basis. The challenge, however, for future research on
human disease is to understand not only the mechanistic
basis, but also the underlying dynamics of gene product
expression. Thus, biological research should emphasize
the analysis of pattern of gene expression over individual
measurements.
GO has been developed to predict behavior of entire bio-
logical systems, being assigned to three aspects: (1) Molec-
ular Function describes activities, such as catalytic or
binding activities, at the molecular level, e.g. kinase activ-
ity. (2) Biological Process describes biological goals accom-
plished by one or more ordered assemblies of molecular
functions, e.g. 'cell death' can have both subtypes, such as
'apoptosis', and subprocesses, such as 'apoptotic chromo-
some condensation'. (3) Cellular Component describes
locations, at the levels of subcellular structures and mac-
romolecular complexes, e.g. 'nuclear inner membrane'
with the synonym 'inner envelope' [4].
The powerful use of comparative gene expression analysis
in human disease was exemplified with a recent study on
gene expression profiles of gastric cancer patients and
their correlation to survival. Leung et al. [5] have shown
that Phospholipase A2 group IIA (PLA2G2A) expression is
associated with prolonged survival and less frequent
metastasis by studying gene expression patterns in human
gastric cancers. This observation was confirmed in an
independent set of patient samples by using quantitative
RT-PCR. Beyond its potential diagnostic and prognostic
significance, this result suggested that the activity of
PLA2G2A may suppress progression or metastasis of
human gastric cancer.
In summary, the application of mathematical models and
computer simulations to analyze gene expression profiles
and to compare complex data sets of various origins may
provide new insight into the pathogenesis of cancer pro-
gression and metastasis. The Gene Ontology (GO) project
http://www.geneontology.org/ provides structured, con-
trolled vocabularies and classifications that cover several
domains of molecular and cellular biology and are freely
available for community use in the annotation of genes,
gene products and sequences.
Translational Research in Drug Discovery: 
Strategies for Complex Systems
Cancer vaccines are promising therapeutics designed to
elicit immune responses against antigens expressed by
tumor cells. However, vaccines that have worked well in
preclinical models have not translated into consistent
responses in the clinic. Since vaccines are comprised of
multiple components, multiple immunological end-
points are used to identify the least effective vaccine com-
ponents in cancer patients. Post-clinical research strategies
are subsequently designed with a focus on improving the
least effective vaccine components.
To improve the performance of cancer vaccines in the clin-
ics, which are traditionally judged by clinical endpoints,
novel endpoints and biomarkers are needed to assist in
understanding why cancer vaccines are not working. From
clinic to bench, a systematic strategy is needed for pre-
clinical optimization that addresses vaccine limitations
identified in the clinics; and from bench to clinic, per-
formance criteria need to be established for a follow-up
clinical study. After gathering the therapeutic options,
testing has to be prioritized on the basis of: a) already
available data; b) availability of the therapeutic modality;
c) models and assays available internally; d) turnaround
time; and e) on the patent landscape.
Prioritization and rapid evaluation of novel therapeutics
will decrease the turnaround time and facilitate decision-
making. However, several tools are needed to make this a
reality. For example, complex therapeutic strategies
require biomarker or even surrogate endpoints from clin-
ical trials to direct development of second-generation
therapeutics. The rapid qualification and choice of surro-
gate endpoints should be based on knowledge gathered
by an "early-stage therapeutic opportunities database".
This comprehensive database should include data on
therapeutic targets, models, assays and published results
and indeed the plethora of new therapeutic strategies in
preclinical stages can only be managed by accessing
informative databases. Moreover, pre-clinical compound
optimization can be facilitated by establishing quantita-
tive endpoints of short duration and lastly go / no go deci-
sion points must be established for surrogate endpoints
and clinical responses in animal models.
However, several current issues of scientific basis also
have to be addressed, such as the importance of clinical
surrogate endpoints, the relevance of animal models, lack
of concordances between assays, and the lack of concord-
ance between surrogate endpoints and the clinical
response, in order to improve cancer vaccine development
strategies.
Applying Translational Research to Drug 
Development
A core principle of TR revolves around validation of tar-
gets, biomarkers and treatment modalities in humans.
These activities and drug development itself cannot be
undertaken without patients or clinical data. How TR can
be integrated in a multi-center, multi-cultural organiza-
tion involving patient accrual from more than 38 different
countries worldwide, for the research and treatment of
cancer can be exemplified by EORTC http://
www.eortc.be, a non-profit organization conducting moreJournal of Translational Medicine 2004, 2:44 http://www.translational-medicine.com/content/2/1/44
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than 100 clinical trials and treating 7000 cancer patients
yearly.
Advancement in basic science and immunology and an
overwhelming revolution of biotechnology have changed
the targets and endpoints in cancer trials from the mere
assessment of cytotoxicity to defined mechanisms for
potential anti-tumor effect. That is in the era of "targeted
therapies" molecular therapeutics are now being designed
to target "strategic" checkpoints that underlie the malig-
nant phenotype. The challenges to be met are: 1) dealing
with new compounds affecting novel molecular targets, 2)
innovation in design and analysis of clinical trials, 3)
cooperation between translational researchers and net-
work of clinical investigators and 4) informed patients.
The major concerns in conducting clinical trials are rising
costs coupled with efficacy rates as low as 5% in cancer
patients, making signal to noise detection not only diffi-
cult but expensive.
The need for research on tumor tissue requires the set-up
of tumor banks and the associated administrative burden
often discourages young oncologists. EORTC established
a tumor bank comprising real tissue samples but includ-
ing a "virtual review" by pathologists. This ensures the
availability of a well-categorized and prognostically eval-
uated collection of primary tumors and allows an online-
searchable bank for researchers to access. Indeed the
tumor bank harbors paraffin-embedded tumors, as well as
frozen tumor tissues http://www.tubafrost.org and stor-
age of tissue is de-centralized at the institute where it is
collected. To assure equal quality of tissue, which in out-
come of scientific experiments can be compared, stand-
ardization of the collection and storage methods is
fundamental. Therefore, protocols for storage, retrieval
and tracking of tissues will be standardized and imple-
mented in all participating laboratories.
Access to the tumor bank allows screening of many avail-
able tumor samples for the expression of molecular tar-
gets and will help to unravel novel biomarkers for
diagnosis and treatment. Such access will allow us to over-
come the missed opportunities due to lack of tissue collec-
tion in clinical trials, which could have allowed better pre-
screening of potentially responsive patients based on
expression of certain biomarkers e.g., expression of bcl-2,
and the treatment of target positive patients may have
ensured a better clinical outcome in this target class.
The challenge of testing promising new modalities for the
cure of disease that had shown efficacy in experimental
models lies in a lack of understanding of the underlying
mechanism, heterogeneity of human genetic backgrounds
and a lack of suitable controls in human studies. Strategies
have been developed at the NIH for the global monitoring
of patients by studying, with high-throughput technology,
the systemic effects of treatments as well as their effect
within the target organ. For this bedside to bench effort, a
systematic sampling of human tissues of local (site of
immunogen application), systemic (circulation) and
peripheral (tumor site) origin needs to be standardized to
ensure high quality of samples avoiding degradation of
protein, RNA and DNA. This TR approach allows experi-
mental studies in human samples during or after therapy
through amplification of transcripts for analysis of mini-
mal sample tissue, and the application of monitoring
techniques for genetic profiling. Further, proteomic-based
approaches allow following the kinetics of the mecha-
nism of actions of therapeutics.
Studying the effects of treatment in a bedside to bench
approach provides markers for the characterization of dis-
ease process and/or testing hypotheses generated by
experimental models. Therefore, the nature of research in
the clinical setting can realistically be described as
'hypothesis generating", rather than 'hypothesis driven',
through a discovery-driven approach. Analysis of the
genetic background can reveal polymorphism of genes
involved in immune reactions, such as cytokines and their
receptors, which might influence the outcome of immu-
nological interventions in different patient populations
[6].
Analysis of disease heterogeneity can be approached by
transcriptional analysis, through linear amplification of
RNA and subsequent analysis by cDNA array and tran-
scriptome array, and/or functional protein analysis,
through protein characterization by proteomics [2,7].
Numerous tumor-antigen based cancer vaccine studies
have shown that there is a functional dissociation
between systemic circulating cytotoxic T cells and tumor
infiltrating T cells (TIL). Tumor antigen-specific T cells
have been demonstrated to have a quiescent phenotype
and consequently cell cycle activation requires antigen-
specific stimulation, as well as non-specific stimulation by
IL-2 [8]. In addition, the local release of immune inhibi-
tory factors by tumor cells is influencing the T cell pheno-
type and cytotoxicity leading either to tumor regression or
recurrence [2]. To understand these complex mechanisms,
it is important to study the tumor microenvironment by
collection of large libraries of relevant clinical specimen,
such as excisional biopsies or fine needle aspirates (FNA).
FNA have the advantage to allow serial sampling of the
same tumor site over time and treatment and to allow a
prospective follow up of a given lesion. Studying of the
tumor microenvironment will provide invaluable insights
into mechanisms involved in disease progression and/or
changes affected by therapy, in terms of genes whose
expression changed due to (1) genetic instability, (2)
immune selection or (3) immune regulation.Journal of Translational Medicine 2004, 2:44 http://www.translational-medicine.com/content/2/1/44
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Despite the many obstacles in monitoring therapeutic
effect in early phase clinical trials and the lack of hypoth-
esis, the scientific significance of these trials should be
reviewed assuming that the new treatment will not be
beneficial. Desirable outcomes include learning about the
disease process, the primary goal of the therapy and the
reasons for its failure. Another concern should be if we
have taken advantage of the patient population accrued at
least to learn something, although independent of treat-
ment, about the disease process itself. Clinical trials
should therefore be designed, within ethical constructs, to
look at questions beyond the ones related solely to treat-
ment. This can be achieved through (1) establishment of
libraries of relevant clinical samples for immediate or
future studies, (2) prospective collection of data into a
consistent format, and (3) tight link between clinical and
scientific data.
Developing better therapies for chronic inflammatory dis-
eases also exemplifies the use of the latest technological
advances in TR such as proteomics, transcriptomics and
cellomics, for identification or application of biomarkers.
Chronic inflammation frequently precedes the develop-
ment of cancer in adults, such as lung [9], esophageal, gas-
tric and pancreatic cancers. This may be due to a switch
from apoptotic (scheduled) to necrotic (unscheduled)
tumor cell death induced by mechanisms related to the
chronicity of the inflammatory response. Acute inflam-
matory processes caused by viral or bacterial infections are
in most cases effectively cleared by the immune system of
a competent host. Some infections and other causes of
inflammation such as solar exposure to the skin, pro-
longed tobacco smoke or chemicals, can also lead to pro-
longed inflammatory processes. In these chronic up-
regulated situations, products of cyclooxygenase activity,
or nitric oxide accumulating at the local inflammatory site
lead to augmented cell proliferation and death. This is
often be linked to hypermethylation of promoter regions
in tumor-suppressor and/or pro-apoptotic genes. Persist-
ence of defects in the apoptotic machinery provokes
necrotic cell death and the release of cellular contents,
which in turn enhances cell growth, cancer progression
and infiltration of leukocytes including tumor-associated
mast cells and macrophages.
Several factors, such as: 1) the nuclear protein HMGB1, 2)
the S100 family of molecules; 3) purine metabolites, ATP,
AMP and uric acid, and 4) heat shock proteins have
emerged as relevant mediators or "endogenous damage or
danger signals" to recruit inflammatory cells, to promote
wound healing and associated stromagenesis, angiogen-
esis; and ultimately to modulate immune functions [10].
Until recently, methods to measure necrotic death in
patients were not available. The application of proteomics
to identify factors, such as HMGB1 in serum of cancer
patients, has revealed elevated serum levels in patients
with metastatic melanoma, pancreatic cancer and others
[10]. The correlation of these serological markers of
necrotic cell death with histological patterns, genetic
resistance to apoptotic death in animal models could lead
to novel targets for immune therapy, such as antibodies to
HMGB1, in order to interrupt the "circolo vizioso" of this
"addiction to death" which promotes tumor growth [9].
Current attempts for cancer therapy focused on vaccina-
tion to antigenic targets or application of cytokines have
resulted in measurable anti-tumor reactivity in the blood;
however, these therapies have mostly failed to show a cor-
relation with tumor outcome or progression. Therefore, to
more completely understand and identify factors assess-
ing tumor death could inform and drive the development
of more effective biological therapies for cancer patients.
Sample acquisition in the blood includes serum/protein
collection for Seldi-Tof mass spectrometry; and the collec-
tion of cells for microarray, proteomics, and high contents
screening via cellomics. Protein chip Seldi-Tof MS has
been already successfully used to discriminate serum
expression profiles in various cancer types [11-13]. The
complexity of these advanced, high-throughput technolo-
gies will exponentially increase the amount of data, with
the consequence that the main activities of future biolog-
ical and medical laboratories will be in data analysis and
integration rather than in data collection. Therefore, spe-
cialized teams are required for collaboration efforts in
order to manage data warehousing, mining and analysis,
and thus establishing networks for the identification and
application of biomarkers.
Beside proper study design, the models chosen to perform
data classification and to estimate classification errors are
highly critical for the complex data analysis. The identifi-
cation of diagnostic markers for cancer, or markers to
identify responders vs. non-responders to therapy
requires systematical analysis of healthy vs. diseased, then
of benign inflammatory disease vs. malignant cancer.
Thus, methods to perform statistical analysis (e.g. permu-
tation, randomization) are powerful, intuitive and pro-
vide an objective position from which to assess results. To
handle these complex data analysis problems, the Univer-
sity of Pittsburgh has formed the Pittsburgh Supercom-
puting Center (PSC) headed by Dr. Arthur W. Wetzel, in a
joint effort with Carnegie Mellon University and Westing-
house Electric Company, and is to date the most powerful
open-resource computer available.
Imaging tools and Technologies for 
Translational Research
There are many examples of the value of weaving molecu-
lar imaging into Investigational New Drug Development.
At the same time, the scale of the initial investmentsJournal of Translational Medicine 2004, 2:44 http://www.translational-medicine.com/content/2/1/44
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required vs. perceived benefits may not gain the necessary
support of decision makers for application into develop-
ment programs. There is a clear need to educate on the
power and limitations of nuclear imaging techniques
within the context of enhancing new drug development.
Within this context, a primary goal for TR is to emphasize
the cultural and operational shifts required of various
stakeholders including academia, in order to better part-
ner with industry.
The term imaging covers a range of available techniques,
including discovery autoradiography, small animal imag-
ing (PET and MRI), traditional anatomical imaging
(Ultrasound, MRI, CT), functional imaging (MRI, PET,
SPECT) and many new tracers are available as are tech-
niques with increased sensitivity to enable micro-doing
studies (AMS) [14]. Nuclear imaging techniques are pow-
erful tools and can be used for a number of development
objectives. These include a number of goals described
below.
Firstly demonstrating drug penetration into the tissue of
interest and co-localization or binding with the intended
target through receptor occupancy (e.g., labeled ligand
displacement), including describing dose vs. target occu-
pancy curves remains a key objective an done used fre-
quently in early clinical research. A second objective
involves the quantification of a compound's pharmacoki-
netic (PK) profile using radio-labeled compound, an anal-
ysis that can be performed on a region of interest basis e.g.
to assess time on target as well as potential therapeutic
benefits vs. side effects. Additionally, imaging can be used
to quantify pharmacodynamic (PD) effects of drug action
and their relationship to administered dose. In combina-
tion, PK/PD information thus derived can be used to
select a dose with which to test the clinical hypothesis or
help quantify the therapeutic index. From a TR perspective
all these techniques can be applied in the discovery and
preclinical phases to facilitate compound selection and
optimization as well as in the clinical phases.
A key question emerges in applying these technologies:
"How best to get it done" and the debate of internal imag-
ing centers vs. external networks and academic relation-
ships quickly emerges. On balance, it is clear that there is
not one ideal solution here rather in general a collabora-
tive approach between industry and academia is recom-
mended. As a consumer of medical imaging, industry is a
critical player in driving innovation and the paradigm
shift towards more frequent yet appropriate utilization.
However, a partnership approach ultimately generates
better value and cost-effectiveness for the Imaging disci-
pline as a whole.
Conclusions and path forwards
TR is an approach to foster communication between the
scientific community and clinical practitioners. To maxi-
mize the value this can bring requires that public and gov-
ernmental education has to be improved in order to
leverage understanding and advocacy. There are many
benefits to be accrued from this, not least of which being
for the patient that is waiting for meaningful therapeutic
advances. New drugs have to be developed fast and show
effect on the right target at the earliest possible stage of
development in order for industry to become more inno-
vative and productive and medicines to be less expensive.
Amongst other specific aspects required, are the strength-
ening of educational opportunities for physician scientists
to help prepare them to conduct effective TR. At the same
time, discovery science should be conducted by scientists
who have been trained in relevant disciplines including
cell biology and pharmacology as well as molecular biol-
ogy. This in turn requires grant support for TR-related
projects. Specifically, young scientific investigators should
have more access to grants from governmental bodies and
foundations in order to conduct research on clinical sam-
ples. This funding is largely in the hands of government
leadership. Other points for disseminated education
include the availability of a plethora of tools available to
conduct and advance TR and development opportunities
that include high quality clinical sample collection.
Lastly, since TR is information intensive, considerable
efforts are required to provide accessible databases and
share knowledge. To help ameliorate this gap and provide
access to information derived from human experimenta-
tion and to optimize the communication between clini-
cians and scientist, Dr. Marincola founded the Journal of
Translational Medicine, an Open Access, peer-reviewed
online journal, so that more therapeutic insights may be
derived from new scientific ideas – and vice versa http://
www.translational-medicine.com.
In conclusion, TR represents a team effort, since no single
constituency can be fluent in all aspects, and thus a con-
certed effort is needed amongst translational researchers
to convince stakeholders and legislators of the need to
support TR efforts, and thus maximize its potential.
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